Arbutus Biopharma Corp - FORM 10-K - EX-21.1 - EXHIBIT 21.1 - March 22, 2017

Attached files

file filename
EX-32.2 - EXHIBIT 32.2 CFO SOX - Arbutus Biopharma Corpexhibit322_soxcertcfo.htm
EX-32.1 - EXHIBIT 32.1 CEO SOX - Arbutus Biopharma Corpexhibit321_soxcertceo.htm
EX-31.2 - EXHIBIT 31.2 10-K CFO - Arbutus Biopharma Corpexhibit312_10-kcertcfo.htm
EX-31.1 - EXHIBIT 31.1 10K CEO - Arbutus Biopharma Corpexhibit311_10-kcertceo.htm
EX-23.1 - EXHIBIT 23.1 - Arbutus Biopharma Corpexhibit231_kpmgconsent.htm
EX-10.67 - EX 10.67 ALEXION LICENSE AGREEMENT - Arbutus Biopharma Corpexhibit1067alexionagreemen.htm
EX-10.66 - EX 10.66 BILL SYMONDS EMPLOY AMEMD - Arbutus Biopharma Corpexhibit1066_billsymonds.htm
EX-10.65 - EX 10.65 CYTOS TERMINATION - Arbutus Biopharma Corpexhibit1065_cytosterminati.htm
EX-10.64 - EX 10.64 DICERNA TERMINATION - Arbutus Biopharma Corpexhibit1064_dicernatermina.htm
EX-10.63 - EXHIBIT 10.63 NEUROVIVE TERMINATION - Arbutus Biopharma Corpexhibit1063_neurovivetermi.htm
EX-10.62 - EX 10.62 DOD TERMINATION - Arbutus Biopharma Corpexhibit1062_dodtermination.htm
10-K - 10-K - Arbutus Biopharma Corparbutus10k2016.htm
Exhibit 21.1
 
Arbutus Biopharma Corporation
 
List of Subsidiaries
 
Name
Date on which the entity
became Arbutus’ wholly
owned sub
Jurisdiction
Protiva Biotherapeutics Inc.
May 30, 2008
British Columbia, Canada
Arbutus Biopharma Inc.
Mar. 4, 2015
Delaware, United States of America


Stock widget

Investing forum

Arbutus Biopharma Corp Reports